The estimated Net Worth of Ashu Tyagi is at least $18.7 million dollars as of 25 September 2018. Ashutosh Tyagi owns over 430,174 units of Y-Mabs Therapeutics Inc stock worth over $18,481,660 and over the last 6 years he sold YMAB stock worth over $0. In addition, he makes $231,540 as Independent Director at Y-Mabs Therapeutics Inc.
Ashutosh has made over 1 trades of the Y-Mabs Therapeutics Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently he bought 430,174 units of YMAB stock worth $6,882,784 on 25 September 2018.
The largest trade he's ever made was buying 430,174 units of Y-Mabs Therapeutics Inc stock on 25 September 2018 worth over $6,882,784. On average, Ashutosh trades about 61,453 units every 0 days since 2018. As of 25 September 2018 he still owns at least 1,392,740 units of Y-Mabs Therapeutics Inc stock.
You can see the complete history of Ashutosh Tyagi stock trades at the bottom of the page.
Dr. Ashutosh Tyagi, M.D., is an Independent Director of the Company. Dr. Tyagi was with Scopia Capital from 2010 to 2018 (as a partner from 2012 to 2018). At Scopia Capital, Dr. Tyagi managed global health care investments and was a Co-Portfolio Manager of Scopia Capital's health care funds. Prior to joining Scopia, he worked at Lombard Odier, Morgan Stanley, and Citigroup. Dr. Tyagi received a B.A. in Asian Studies from the University of Michigan, an MBA from the University of Michigan Business School and an M.D. from the University of Michigan School of Medicine. Dr. Tyagi currently serves as Chair of our Nominating and Corporate Governance Committee and, if elected as a Class II director at the Annual Meeting, he will continue to serve in that capacity.
As the Independent Director of Y-Mabs Therapeutics Inc, the total compensation of Ashutosh Tyagi at Y-Mabs Therapeutics Inc is $231,540. There are 8 executives at Y-Mabs Therapeutics Inc getting paid more, with Claus Moller-San Pedro having the highest compensation of $967,497.
Ashutosh Tyagi is 43, he's been the Independent Director of Y-Mabs Therapeutics Inc since 2017. There are 17 older and 2 younger executives at Y-Mabs Therapeutics Inc. The oldest executive at Y-Mabs Therapeutics Inc is Dr. Torben Lund-Hansen, 70, who is the Sr. VP & Chief Technical Officer.
Ashu's mailing address filed with the SEC is C/O Y-MABS THERAPEUTICS, INC., 230 PARK AVENUE, SUITE 3350, NEW YORK, NY, 10169.
Over the last 6 years, insiders at Y-Mabs Therapeutics Inc have traded over $85,284,951 worth of Y-Mabs Therapeutics Inc stock and bought 1,819,126 units worth $23,554,756 . The most active insiders traders include James Healy, Thomas Gad et Johan Wedell Wedellsborg. On average, Y-Mabs Therapeutics Inc executives and independent directors trade stock every 14 days with the average trade being worth of $494,414. The most recent stock trade was executed by Torben Lund Hansen on 28 August 2024, trading 50,000 units of YMAB stock currently worth $219,000.
y-mabs is late-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. the company has a broad and advanced product pipeline, including 2 pivotal-stage product candidates - naxitamab and omburtamab - which target tumors that express gd2 and b7-h3, respectively. our mission is to become the world leader in developing antibody-based cancer products that address clear unmet needs in pediatric oncology. with the right partnerships and collaboration, we envision expanding our capabilities to treat adults - changing the course of cancer and its outcome.
Y-Mabs Therapeutics Inc executives and other stock owners filed with the SEC include: